Harold Kalant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Harold Kalant has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Dzung Anh Lê
Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada, M5S 1A8
1 shared publicationJoanne Chiu
Department of Pharmacology, University of Toronto, Ontario, Canada
1 shared publication
Latest Publications
- 1 August 2016
- Published by Elsevier in International Journal of Drug Policy
- Vol. 34, 17-19
Points of agreement and difference: A rejoinder to Fischer et al.
- 1 August 2016
- Published by Elsevier in International Journal of Drug Policy
- Vol. 34, 17-19
Points of agreement and difference: A rejoinder to Fischer et al.
- 1 August 2016
- Published by Elsevier in International Journal of Drug Policy
- Vol. 34, 5-10
A critique of cannabis legalization proposals in Canada
- 1 August 2016
- Published by Elsevier in International Journal of Drug Policy
- Vol. 34, 5-10
A critique of cannabis legalization proposals in Canada
- 16 March 2015
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 97 (6) , 538-540
Cannabis control policy: No rational basis yet for legalization
- 16 March 2015
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 97 (6) , 538-540
Cannabis control policy: No rational basis yet for legalization
- Open Access
- 1 September 2014
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 42 (2) , 146-148
Cannabis in the Treatment of Rheumatic Diseases: Suggestions for a Reasoned Approach
- 1 September 2014
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 42 (2) , 146-148
Open AccessCannabis in the Treatment of Rheumatic Diseases: Suggestions for a Reasoned Approach
Drug classification: science, politics, both or neither?
Governments currently classify illicit drugs for various purposes: to guide courts in the sentencing of convicted violators of drug control laws, to prioritize targets of prevention measures and to educate the public about relative risks of the various drugs. It has been proposed that classification should be conducted by scientists and drug experts rather than by politicians, so that it will reflect only accurate factual knowledge of drug effects and risks rather than political biases. Although this is an appealing goal, it is inherently impossible because rank‐ordering of the drugs inevitably requires value judgements concerning the different types of harm. Such judgements, even by scientists, depend upon subjective personal criteria and not only upon scientific facts. Moreover, classification that is meant to guide the legal system in controlling dangerous drug use can function only if it is in harmony with the values and sentiments of the public. In some respects, politicians may be better attuned to public attitudes and wishes, and to what policies the public will support, than are scientific experts. The problems inherent in such drug classification are illustrated by the examples of cannabis and of salvinorin A. They raise the question as to whether the classification process really serves any socially beneficial purpose.
Drug classification: science, politics, both or neither?
Governments currently classify illicit drugs for various purposes: to guide courts in the sentencing of convicted violators of drug control laws, to prioritize targets of prevention measures and to educate the public about relative risks of the various drugs. It has been proposed that classification should be conducted by scientists and drug experts rather than by politicians, so that it will reflect only accurate factual knowledge of drug effects and risks rather than political biases. Although this is an appealing goal, it is inherently impossible because rank‐ordering of the drugs inevitably requires value judgements concerning the different types of harm. Such judgements, even by scientists, depend upon subjective personal criteria and not only upon scientific facts. Moreover, classification that is meant to guide the legal system in controlling dangerous drug use can function only if it is in harmony with the values and sentiments of the public. In some respects, politicians may be better attuned to public attitudes and wishes, and to what policies the public will support, than are scientific experts. The problems inherent in such drug classification are illustrated by the examples of cannabis and of salvinorin A. They raise the question as to whether the classification process really serves any socially beneficial purpose.
What neurobiology cannot tell us about addiction
Molecular neurobiological studies have yielded enormous amounts of valuable information about neuronal response mechanisms and their adaptive changes. However, in relation to addiction this information is of limited value because almost every cell function appears to be involved. Thus it tells us only that neurons adapt to ‘addictive drugs’ as they do to all sorts of other functional disturbances. This information may be of limited help in the development of potential auxiliary agents for treatment of addiction. However, a reductionist approach which attempts to analyse addiction at ever finer levels of structure and function, is inherently incapable of explaining what causes these mechanisms to be brought into play in some cases and not in others, or by self‐administration of a drug but not by passive exposure. There is abundant evidence that psychological, social, economic and specific situational factors play important roles in initiating addiction, in addition to genetic and other biological factors. Therefore, if we hope to be able to make predictions at any but a statistical level, or to develop effective means of prevention, it is necessary to devise appropriate integrative approaches to the study of addiction, rather than pursue an ever‐finer reductive approach which leads steadily farther away from the complex interaction of drug, user, environment and specific situations that characterizes the problem in humans.
What neurobiology cannot tell us about addiction
Molecular neurobiological studies have yielded enormous amounts of valuable information about neuronal response mechanisms and their adaptive changes. However, in relation to addiction this information is of limited value because almost every cell function appears to be involved. Thus it tells us only that neurons adapt to ‘addictive drugs’ as they do to all sorts of other functional disturbances. This information may be of limited help in the development of potential auxiliary agents for treatment of addiction. However, a reductionist approach which attempts to analyse addiction at ever finer levels of structure and function, is inherently incapable of explaining what causes these mechanisms to be brought into play in some cases and not in others, or by self‐administration of a drug but not by passive exposure. There is abundant evidence that psychological, social, economic and specific situational factors play important roles in initiating addiction, in addition to genetic and other biological factors. Therefore, if we hope to be able to make predictions at any but a statistical level, or to develop effective means of prevention, it is necessary to devise appropriate integrative approaches to the study of addiction, rather than pursue an ever‐finer reductive approach which leads steadily farther away from the complex interaction of drug, user, environment and specific situations that characterizes the problem in humans.